

Edrecolomab

Cat. No.:	HY-P99231
CAS No.:	156586-89-9
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Edrecolomab (Panorex) is a murine monoclonal antibody to the cell-surface glycoprotein 17-1A, expressed on epithelial tissues and on various carcinomas. Edrecolomab shows anti-tumor activity and can be used in colorectal carcinoma research ^{[1][2]} .	
In Vitro	Edrecolomab (0-100 µg/mL; 20 h) shows moderate antibody-dependent cellular cytotoxicity (ADCC) ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Cytotoxicity Assay ^[1]	
	Cell Line:	KATO III cells
	Concentration:	0-100 µg/mL
	Incubation Time:	20 hours
	Result:	Exhibited an ED ₅₀ value > 100 ng/mL.
In Vivo	Edrecolomab (intravenous injection; 30 µg/dose; day 1, 4 and 7 after tumor-cell inoculation) treatment inhibits tumor growth in the HT-29 nude mouse model ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	Male nu/nu mice injected with HT-29 colon carcinoma cells ^[1]
	Dosage:	30 µg/dose
	Administration:	Intravenous injection; 30 µg/dose; day 1, 4 and 7 after tumor-cell inoculation
	Result:	Inhibited tumor growth with a number of significant readings (p ≤ 0.05).

REFERENCES

[1]. Naundorf S, et al. In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment. Int J Cancer. 2002 Jul 1;100(1):101-10.

[2]. Punt CJ, et al. Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study. Lancet. 2002 Aug 31;360(9334):671-7.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA